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Introduction
Growth factors regulate key aspects of cellular life such as pro-
liferation, differentiation, migration, and death. Pattern forma-
tion and organogenesis during development, along with tissue 
regeneration and repair during adulthood, are dependent on 
strictly regulated action of growth factors. However, deregu-
lated activity of these factors or their downstream signaling 
pathways can result in developmental disorders as well as con-
tribute to a wide variety of cancers. In fact, loss of function mu-
tations of growth factor signaling antagonists or gain of function 
mutations of growth factor signaling agonists are a hallmark of 
many tumors (Vogelstein and Kinzler, 2004).
Precise regulation of growth factor signaling is achieved 
by a large body of extrinsic and intrinsic regulators of signaling, 
the majority of which remain poorly defined. Sprouty related 
with EVH1 domain (Spred) and its related Sprouty proteins are 
two such families of intrinsic signaling regulators that inhibit   
the RAF–MEK (MAPK/extracellular signal-regulated kinase 
[ERK])–ERK (ERK1/2) pathway downstream of a variety of 
stimuli (Hacohen et al., 1998; Casci et al., 1999; Kramer et al., 
1999; Reich et al., 1999; Wakioka et al., 2001; Kato et al., 2003; 
Nonami et al., 2004; Bundschu et al., 2005; King et al., 2005; 
Sivak et al., 2005). Sprouty was initially discovered in Drosophila 
melanogaster as a negative regulator of Bnl (Branchless) FGF 
signaling during development of the tracheal system (Hacohen 
et al., 1998) but was subsequently shown to attenuate signaling 
from other growth factors of the receptor Tyr kinase (RTK) fam-
ily as well, establishing it as a general RTK antagonist (Casci   
et al., 1999; Kramer et al., 1999; Reich et al., 1999). However, 
vertebrate Sproutys were shown to inhibit ERK1/2 downstream 
of only a subset of RTK growth factors such as FGF and VEGF 
but not EGF (Minowada et al., 1999; Impagnatiello et al., 2001).
All  Sprouty  proteins  share  a  characteristic  Cys-rich   
C-terminal domain (SPRY domain), which is believed to be indis-
pensable for their function (Casci et al., 1999; Yigzaw et al., 
T
he potential for modulation of growth factor signal-
ing by endocytic trafficking of receptors is well rec-
ognized, but the underlying mechanisms are poorly 
understood.  We  examined  the  regulation  of  fibroblast 
growth  factor  (FGF)  signaling  by  Sprouty  related  with 
EVH1 (Ena/VASP homology 1) domain (Spred), a family 
of signaling inhibitors with proposed tumor-suppressive 
functions. The inhibitory activity of Spreds has been linked 
to their N-terminal EVH1 domain, but the molecular mech-
anism is unknown. In this study, we identify a novel late 
endosomal protein that directly binds to the EVH1 domain 
of Spred2. Neighbor of BRCA1 (NBR1) is a highly con-
served multidomain protein that interacts and colocalizes 
with Spred2 in vivo. Attenuation of FGF signaling by 
Spred2 is dependent on the interaction with NBR1 and is 
achieved by redirecting the trafficking of activated recep-
tors to the lysosomal degradation pathway. Our findings 
suggest a critical function for NBR1 in the regulation of 
receptor trafficking and provide a mechanism for down-
regulation of signaling by Spred2 via NBR1.
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yeast two-hybrid screen of a human skeletal muscle cDNA   
library (5 × 10
5 colonies), we identified NBR1 as a novel 
binding partner. Of the total 22 positive hits, >70% corre-
sponded to the C-terminal end of NBR1. The shortest cDNA 
encoded for the 131 C-terminal amino acids of the protein, 
suggesting that the binding site for the Spred2 EVH1 domain 
is located within these 131 amino acids (Fig. 1 A). The exis-
tence of a direct interaction between this region of NBR1 and 
the EVH1 domain of Spred2 was further confirmed by a di-
rected yeast two-hybrid assay (Fig. S1 A) as well as an in vitro 
pull-down  experiment  (Fig.  S1  B).  It  should  be  noted  that 
there  are  no  canonical  Pro-rich  EVH1-binding  sequences 
within  this  region  of  NBR1  in  accord  with  the  previously 
solved tertiary structure of the Spred EVH1 domain, which in-
dicates a distinct binding mechanism to other EVH1 domains 
(Harmer et al., 2005).
We then performed coimmunoprecipitation (co-IP) exper-
iments in mammalian cells to confirm the existence of an inter-
action in vivo. GFP-tagged NBR1 could be immunoprecipitated 
with myc-Spred2 in human embryonic kidney 293T cells 
(Fig. S1 C). Endogenous NBR1 could similarly be immuno-
precipitated with myc-Spred2 in 293T cells (Fig. 1 B). We also 
found in these experiments that endogenous P62, another PB1 
domain– and UBA domain–containing protein which is known 
to interact with NBR1 (Lange et al., 2005), also coimmuno-
precipitated with myc-Spred2 (Fig. 1 B). Interestingly, although 
endogenous NBR1 appeared as a doublet in 293T cell lysates, 
only the higher migrating band seemed to be immunoprecipi-
tated with Spred2 (Fig. 1 B).
To confirm the interaction of NBR1 with SPRED2 in a 
physiological context, we used a neuronal cell line (SH-SY5Y 
neuroblastoma), as SPRED2 has been shown to be expressed 
at relatively high levels in neuronal tissues (Engelhardt et al., 
2004; Bundschu et al., 2006). Endogenous NBR1 could be 
immunoprecipitated with endogenous SPRED2 in these cells 
(Fig. 1 C), supporting the existence of a Spred–NBR1 inter-
action at physiological protein levels. Finally, as predicted 
from the yeast two-hybrid assay, the interaction of Spred2 
with endogenous NBR1 in vivo was dependent on the EVH1 
domain (Fig. 1 D). Surprisingly, the SPRY domain was also 
necessary for an interaction in vivo, whereas KBD was dis-
pensable (Fig. 1 D).
Spred2 colocalizes with NBR1 in an EVH1 
domain–dependent manner
Next, we investigated the subcellular localization of Spred2 
and NBR1 by confocal microscopy. In COS-7 cells, we found 
that the majority of ectopically expressed Spred2 exhibited a 
cytoplasmic punctuate staining (Fig. 2 A). Similar staining 
was observed for endogenous SPRED2 in SH-SY5Y neuro-
blastoma cells (Fig. 2 B), ruling out the possibility of an arti-
fact caused by overexpression. To investigate the subcellular 
localization of NBR1, we transfected COS-7 cells with a   
C-terminally GFP-tagged NBR1 construct. NBR1-GFP was 
found to localize to the limiting membranes of some peri-
nuclear vesicular structures (Fig. 2 C). These vesicles were occa-
sionally found attached to one another, which gave them an 
2001; Hanafusa et al., 2002). Spreds also contain a C-terminal 
SPRY domain but diverge from Sproutys by further containing 
a central Kit-binding domain (KBD) and an N-terminal EVH1 
(Ena/VASP homology 1) domain (Wakioka et al., 2001). More-
over, Spreds are divergent with regard to their target stimuli, in-
hibiting ERK1/2 downstream of a diverse group of RTK and 
non-RTK factors such as FGF, EGF, cytokines, and chemokines 
(Wakioka et al., 2001; Kato et al., 2003; Nonami et al., 2004; 
Bundschu et al., 2005; King et al., 2005; Sivak et al., 2005).
Similar to Sproutys, Spreds are thought to be potential   
tumor suppressors, as expression of both Spred1 and -2 has been 
shown to be reduced in human hepatocellular carcinomas, with 
levels  negatively  correlating  with  malignancy  (Yoshida  et  al., 
2006). Apart from their role as potential tumor suppressors, 
knockout studies have highlighted the involvement of Spreds in 
bone morphogenesis (Bundschu et al., 2005), hematopoiesis 
(Nobuhisa et al., 2004), allergen-induced airway eosinophilia, 
and hyperresponsiveness (Inoue et al., 2005). Furthermore, Spreds 
have been implicated along with Sproutys in the regulation of 
Xenopus laevis gastrulation and mesoderm formation downstream 
of FGF, although both the timing and the target pathway of Spreds 
seemed to be distinct from that of Sproutys (Sivak et al., 2005).
Previous studies have shown that the N-terminal EVH1 
domain of Spreds is essential for their inhibitory activity on 
ERK1/2 (Wakioka et al., 2001; King et al., 2005). However, the 
molecular  mechanism  of  this  EVH1-dependent  action  is  un-
known. Because EVH1 domains are protein–protein interaction 
modules (Ball et al., 2002), we hypothesized that an unidentified 
critical partner of Spreds might interact with the EVH1 domain 
to mediate their function. Therefore, we used a yeast two-hybrid 
approach, using the EVH1 domain of Spred2 as bait to identify 
candidate partners. We identified neighbor of BRCA1 (NBR1), a 
multidomain protein which contains several putative protein–
protein interaction modules, an N-terminal homo/hetero-
dimerization PB1 (Phox and Bem1p1) domain, a ZINC finger, a 
coiled-coil region, and a C-terminal ubiquitin-associated (UBA) 
domain. NBR1 has been previously implicated in signal trans-
duction downstream of the giant muscle kinase Titin (Lange et al., 
2005), but its roles outside the muscle context are otherwise 
poorly characterized. In this study, we show that NBR1 is a spe-
cific late endosomal protein. Spred2 interacts and colocalizes 
with NBR1 in an EVH1 domain–dependent manner in vivo. 
Moreover, inhibition of ERK1/2 by Spred2 is dependent on its 
interaction with NBR1 and is achieved by targeting activated re-
ceptors to the lysosomal degradation pathway. Our findings pro-
vide a mechanism for the EVH1-dependent actions of Spred2 
and implicate NBR1 as a novel regulator of receptor trafficking 
and signaling for the first time. These results further support the 
notion that alteration of receptor trafficking itinerary could be a 
common means for regulation of downstream signaling.
Results
NBR1 is a novel EVH1 domain binding 
partner of Spred2
Using the EVH1 domain of murine Spred2 (mSpred2), which 
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NBR1 specifically localizes to the limiting 
membrane of late endosomes
We next set out to characterize the vesicular structures to which 
NBR1 was localized. No colocalization was observed between 
NBR1-GFP and the early endosomal marker EEA1 (Fig. 4 A) 
or the recycling endosomal marker RAB11 (Fig. 4 B). The 
same was also observed with another early endocytic marker, 
RAB5 (Fig. S2 A). However, a very strong colocalization was 
detected between NBR1 and the late endosomal/lysosomal 
marker LAMP2 (Fig. 4 C) or RAB7 (Fig. S2 B). To discrimi-
nate between late endosomes and lysosomes, we used an anti-
body  against  mannose  6-phosphate  receptor  (MPR),  a  late 
endosomal marker which is specifically absent in lysosomes.   
A strong colocalization between NBR1-GFP and MPR was de-
tected (Fig. 4 D). Conversely, when LysoTracker red was used, 
an acidotrophic dye which specifically stains lysosomes, no 
colocalization with NBR1-GFP was observed (Fig. 4 E). Simi-
larly, no colocalization was observed between LysoTracker red 
and myc-tagged Nbr1, ruling out the possibility of GFP inacti-
vation as the result of low lysosomal pH (Fig. S2 C). This was 
while myc-Nbr1 and LAMP2 still perfectly colocalized (un-
published data). Late endosomal localization of NBR1 could 
also be shown for endogenous NBR1 in cells treated with BafA 
(Fig. 4 F). Finally, no colocalization was also observed between 
NBR1-GFP and the caveosome marker CAV1 (Fig. S2 D) or 
NBR1-GFP and GM130, a specific Golgi marker (Fig. S2 E). 
These results collectively show that NBR1-positive vesicles 
are specifically late endosomal in character. As NBR1 gets de-
graded in lysosomes (Kirkin et al., 2009), we therefore believe 
that its specific late endosomal localization is a steady-state 
phenomenon, being continuously trafficked from late endosomes 
to lysosomes but then getting rapidly degraded and therefore 
aggregate-like appearance, but this was dependent on the level 
of NBR1-GFP expression. The same vesicular localization 
was observed with an N-terminally GFP-tagged mNbr1 (un-
published data), suggesting that it must be a conserved feature 
and that it is not affected by the position of the tag. Endoge-
nous levels of NBR1 were below detection limits by immuno-
fluorescence in all cells that we investigated. However, while 
this manuscript was being revised, two other papers were pub-
lished showing that by treating the cells with the lysosomal 
inhibitor bafilomycin A1 (BafA), endogenous NBR1 levels 
could be increased to immunofluorescence-detectable levels, 
as NBR1 is degraded via the lysosomal degradation pathway 
(Kirkin et al., 2009; Waters et al., 2009). This was in fact the 
case, and we could detect endogenous NBR1 in COS-7 cells 
treated with BafA (Fig. 2 D). Similar to GFP-tagged NBR1, 
endogenous NBR1 also exhibited a vesicular localization in 
these cells (Fig. 2 D).
We next investigated whether NBR1 and SPRED2 colocal-
ize  in  vivo.  In  BafA-treated  SH-SY5Y  cells,  endogenous 
NBR1  and  SPRED2  colocalized  in  cytoplasmic  punctae 
(Fig. 2 E). Similarly, ectopically expressing Spred2 and NBR1-
GFP were found to colocalize in vivo (Fig. 3 A). In agreement 
with the IP results (Fig. 1 D), deletion of either the EVH1 or 
SPRY domain abolished this colocalization, whereas deletion 
of KBD had no effect (Fig. 3, B–D). Interestingly, deletion of 
the SPRY domain had a profound effect on Spred2 localization, 
causing it to entirely lose its punctate cytoplasmic localization 
and mainly mislocalize to the nucleus (Fig. 3 D). This finding 
can explain why both the EVH1 and SPRY domains of Spred2 
are found to be required for an interaction in vivo (Fig. 1 D): 
EVH1 is required for protein–protein interaction, and SPRY is 
required for vesicular localization.
Figure  1.  NBR1  is  a  novel  Spred2  binding 
partner.  (A)  A  schematic  representation  of 
Spred2  and  NBR1  domains.  The  N-terminal 
EVH1  domain  of  Spred2  was  used  as  bait 
in  a  yeast  two-hybrid  screen  that  identified 
NBR1. The shortest cDNA of NBR1 identified 
coded  for  the  131  C-terminal  amino  acids. 
CC,  coiled-coil;  hNBR1,  human  NBR1;  ZZ, 
ZZ-type ZINC finger domain. (B) Endogenous 
NBR1 as well as its interacting protein P62 
can be immunoprecipitated with myc-tagged 
Spred2 from 293T cell lysates, irrespective of 
FGF2 stimulation. IP and WCL samples were 
immunoblotted  with  the  indicated  antibodies   
(IB).  (C)  Endogenous  NBR1  can  also  be   
immunoprecipitated with endogenous Spred2 
from  SH-SY5Y  neuroblastoma  cell  lysates   
using an anti-Spred2 antibody, irrespective of   
FGF2 stimulation. Approximately 4 mg of cell 
lysate was used for each IP along with 15 µg 
of either anti-Spred2 or nonspecific rabbit IgG 
antibodies. (D) Both the EVH1 and SPRY do-
mains of Spred2 are necessary for the inter-
action with NBR1 in vivo. Endogenous NBR1 
can only be immunoprecipitated from 293T cell 
lysates with either wild type (WT) or the KBD-
deleted mutant of Spred2 but not the EVH1 do-
main– or SPRY domain–deleted mutants. Note 
that in all sections, film exposure times for the 
NBR1 WCL blots were significantly more than 
for the NBR1 IP blots. TUB, tubulin.JCB • VOLUME 187 • NUMBER 2 • 2009   268
dimension as a single high molecular mass multiprotein com-
plex that could be disrupted with pretreatment of the lysate 
with  1%  SDS  (Fig.  S3  C).  Therefore,  we  conclude  that  a 
NBR1–P62–SPRED multiprotein complex might exist in the 
late endosomal compartment in vivo.
ERK1/2 inhibition by Spred2 is dependent 
on the interaction with NBR1
We next investigated the functional significance of the inter-
action with NBR1 for Spred2-mediated inhibition of ERK1/2. We 
observed that expression of myc-tagged Spred2 in 293T cells 
reduced FGF2-mediated ERK1/2 activity at various time points 
after stimulation (Fig. 5 A and Fig. S4 A). In agreement with 
previous studies (Wakioka et al., 2001; King et al., 2005), this 
not detected in significant levels within the lysosomal compart-
ment of our cells.
Late endocytic localization of NBR1 is interesting in 
the  view  that  NBR1  partner  P62  has  also  been  previously 
shown to localize to the late endosomal/lysosomal compartment 
(Sanchez et al., 1998). In fact, we could show that a strong co-
localization existed between P62 and NBR1 when both pro-
teins were expressed in COS-7 cells (Fig. S3 A). When Spred2 
was also expressed, it colocalized with NBR1–P62-positive 
endosomes (Fig. S3 B), which is in agreement with the earlier 
co-IP results (Fig. 1 B). Furthermore, when lysates of 293T 
cells ectopically expressing NBR1, P62, and Spred2 were sub-
jected to blue native/SDS two-dimensional gel electrophore-
sis,  a  fraction  of  these  proteins  co-migrated  in  the  native 
Figure 2.  Endogenous NBR1 and Spred colocalize with each other. (A) The majority of myc-Spred2 in COS-7 cells exhibits a punctate cytoplasmic staining. 
(B) Endogenous SPRED2 also localizes to cytoplasmic punctae in SH-SY5Y neuroblastoma cells. (C) GFP-tagged NBR1 is localized to the limiting membrane 
of some vesicular structure in COS-7 cells. (D) Endogenous NBR1 similarly localizes to vesicular structures in COS-7 cells treated with BafA. (E) Endogenous 
NBR1 colocalizes with endogenous SPRED2 in SH-SY5Y cells treated with BafA. (D and E) Cells were subjected to 200 nM BafA for 16 h before analysis. 
(A–E) Images on the right (A–D) or insets (E) are higher magnifications of the boxed areas. Bars, 10 µm.269 SPRED2 DOWN-REGULATES SIGNALING VIA NBR1 • Mardakheh et al.
its own, NBR1 did not reduce ERK1/2 activity (Fig. 5 B). 
However, when coexpressed along with Spred2, NBR1 further 
enhanced Spred2-mediated ERK1/2 inhibition (Fig. 5 B). This 
enhancement  of  Spred2  activity  supports  the  notion  that   
the formation of a Spred2–NBR1 complex is important for 
Spred2-mediated  inhibition  of  ERK1/2,  as  coexpression  of 
NBR1 must be forcing more of Spred2 into forming a com-
plex with NBR1.
Subsequently, we assessed the effect of endogenous NBR1 
depletion by siRNA on Spred2 function. We used a tetracycline 
inhibition of ERK1/2 activity by Spred2 was dependent on both 
EVH1 and SPRY domains (Fig. 5 A), the two domains which 
were also essential for interaction and colocalization with NBR1 
(Figs. 1 D and 3, B and D). In contrast, KBD, which was shown 
to be dispensable for interaction and colocalization with NBR1 
(Figs. 1 D and 3 C), did not affect Spred2-mediated inhibition 
of ERK1/2 (Fig. 5 A). Therefore, ERK1/2 inhibition by Spred2 
mutants correlates with their ability to interact with NBR1.
We  then  investigated  whether  NBR1  could  cooperate 
with Spred2 in inhibiting ERK1/2 activity. When expressed on 
Figure 3.  Colocalization of Spred2 with NBR1 is 
dependent on both the EVH1 and SPRY domains. 
(A) NBR1-GFP colocalizes with WT myc-Spred2 
in COS-7 cells. (B) NBR1-GFP does not colocalize 
with  EVH1-deleted  myc-Spred2.  (C)  NBR1-GFP 
colocalization with myc-Spred2 is not affected by 
deletion of the KBD. (D) NBR1-GFP colocalization 
with myc-Spred2 also depends on the presence of   
the SPRY domain, probably because of the mis-
localization of SPRY-deleted Spred2 to the nucleus. 
(A–D) Images on the right are higher magnifica-
tions of the boxed areas on the left. Bars, 10 µm.JCB • VOLUME 187 • NUMBER 2 • 2009   270
Figure 4.  NBR1 is specifically localized to the 
limiting membrane of late endosomes. (A) No 
colocalization between NBR1-GFP and endog-
enous EEA1, the marker of early endosomes, 
is seen in COS-7 cells. (B) No colocalization is 
also observed between NBR1-GFP and RAB11, 
the marker of recycling endosomes. (C) A strong   
colocalization  is  detected  between  the  late 
endosomal/lysosomal  marker  LAMP2  and 
NBR1-GFP. (D and E) NBR1-GFP also colocal-
izes strongly with the specific late endosomal 
marker  MPR  (D)  but  not  with  lysosomes  that   
stain positive for LysoTracker red (E). (F) Endog-
enous  NBR1  also  colocalizes  with  the  late   
endosomal/lysosomal marker LAMP2 in COS-7 
cells  treated  with  BafA.  Cells  were  subjected   
to  200  nM  BafA  for  16  h  before  analysis.   
(A–F) Insets are higher magnifications of their 
associated pictures. Bars, 10 µm.271 SPRED2 DOWN-REGULATES SIGNALING VIA NBR1 • Mardakheh et al.
inhibition (Fig. 5 C). To rule out the possibility of an off-target 
effect,  two  independent  siRNA  oligonucleotides  were  used, 
both of which gave similar results (Fig. 5 C). These results re-
veal that Spred2-mediated inhibition of ERK1/2 activity is de-
pendent on NBR1. Interestingly, as we tried to improve the 
(Tet)-inducible construct to make sure that Spred2 was ex-
pressed only after NBR1 was sufficiently depleted. Although 
induction of Spred2 in a control siRNA background inhibited 
ERK1/2 activity as expected (Fig. 5 C), knockdown of NBR1 
by specific siRNA oligonucleotides significantly reduced this 
Figure 5.  Inhibition of ERK1/2 activity by Spred2 is dependent on the interaction with NBR1. (A, left) 293T cells stimulated with FGF2 in the presence of 
WT or various deletion mutants of myc-Spred2 were analyzed by IB for ERK1/2 activity. Inhibition of ERK1/2 by myc-Spred2 was significantly reduced 
by the loss of both the EVH1 and SPRY domains but not KBD. (right) Densitometric analysis of pERK1/2 levels from left. The p-values were calculated using 
one-tailed nonpaired t tests (n = 6). NC, negative control. (B) NBR1 overexpression enhances Spred2-mediated ERK1/2 inhibition. (left) GFP or NBR1-GFP 
plus either empty vector– or myc-Spred2–cotransfected 293T cells were FGF2 stimulated. NBR1-GFP on its own did not affect pERK1/2 levels, but when 
coexpressed with myc-Spred2, it significantly enhanced the ability of Spred2 to reduce pERK1/2 levels. Threefold more NBR1-GFP (or GFP for controls) 
was transfected to ensure that the majority of myc-Spred2–expressing cells also expressed NBR1-GFP. (right) Densitometric analysis of the pERK1/2 levels 
from the left. The p-value was calculated using a one-tailed paired t test (n = 3). (C) Depletion of endogenous NBR1 impairs Spred2 activity. (left) 293T cells 
were double transfected (with 100 pmol and then 50 pmol per 10-cm well) with either nonsilencing control or NBR1-specific siRNA oligonucleotides. The 
Tet-inducible Spred2 construct was cotransfected with TR (1:6 ratio to ensure that every Spred-transfected cell also expressed TR) along with the oligonucleo-
tides on the second transfection. Spred2 expression was induced 6 h before stimulation by 1 µg/ml Tet. Two independent NBR1 siRNA oligonucleotides 
were used (Oligo1 and -2). Spred2 inhibition of ERK1/2 activity was significantly reduced in both cases. (right) Densitometric analysis of the left. The 
p-value was calculated using a one-tailed paired t test (n = 5). (D) Ectopic expression of NBR1 can rescue NBR1 interaction with the EVH1-deleted Spred2 
mutant in a cell type–specific manner. 293T or COS-7 cells overexpressing NBR1-GFP along with WT myc-Spred2, EVH1 myc-Spred2, or empty vector 
as negative control were subjected to IP by myc antibody. Although, like endogenous NBR1, the interaction of ectopic NBR1 with Spred2 was EVH1 
domain dependent in COS-7 cells, ectopic NBR1 could still interact with EVH1 Spred2 in 293T cells. Note that the film exposure time for the NBR1 WCL 
blot was significantly more than for the NBR1 IP blot. (E) Rescuing the NBR1–Spred2 interaction also rescues the function of a noninteracting, otherwise 
nonfunctional EVH1 Spred2 mutant. (left) 293T cells expressing either GFP or NBR1-GFP plus WT myc-Spred2, EVH1 myc-Spred2, or empty vector as 
negative control were stimulated with FGF2 as shown. EVH1 myc-Spred2 could not reduce ERK1/2 activity alone, but pERK1/2 reduction by the EVH1 
myc-Spred2 mutant was rescued back to WT levels when ectopic NBR1-GFP was also expressed to rescue the interaction. NBR1-GFP expression on its own 
did not reduce ERK1/2 activity. Threefold more NBR1-GFP (or GFP for controls) was transfected to ensure that the majority of Spred2-expressing cells also   
expressed NBR1-GFP. (right) Densitometric analysis of the left. The p-value was calculated using a one-tailed paired t test (n = 3). TUB, tubulin. (A–C and E) 
Error bars represent SEM.JCB • VOLUME 187 • NUMBER 2 • 2009   272
Figure 6.  Spred2 targets activated receptors to the lysosomal degradation pathway in an EVH1 domain–dependent manner. (A) Spred2 expression 
results in degradation of ectopic active FGFR1. (left) Levels of ectopic active FGFR1 are significantly decreased in lysates of myc-Spred2– but not GFP 
control–cotransfected 293T cells, whereas those of ectopic TrfR1-GFP or downstream signaling components such as ERK, C-RAF, or GRB2 do not change. 
Fivefold more Spred2 (or GFP for controls) was transfected to ensure that the majority of receptor-expressing cells also coexpressed myc-Spred2. (right) 
Densitometric analysis of the left for TrfR1 and FGFR1. The p-value was calculated using a one-tailed paired t test (n = 3). (B) Spred2-mediated degradation 
of FGFR1 is via the lysosomal degradation pathway. (left) Treatment of 293T cells 1 h before transfection with BafA hinders myc-Spred2–mediated FGFR1 273 SPRED2 DOWN-REGULATES SIGNALING VIA NBR1 • Mardakheh et al.
Spred2 targets activated receptors for 
lysosomal degradation in an EVH1 domain–
dependent manner
Finally, we addressed the mechanism by which Spred2 results 
in  attenuation  of  signaling.  Considering  the  localization  of 
NBR1 to the late endosomal compartment, we reasoned that 
Spred2 might regulate the endocytic trafficking of activated 
receptors via interaction with NBR1. It is widely recognized 
that receptor endocytosis can act to down-regulate signaling 
by targeted degradation of activated receptors via the lyso-
somal degradation pathway. Therefore, we examined whether 
Spred2  acts  to  enhance  degradation  of  activated  receptors. 
293T cells were transfected with either FGF receptor 1 (FGFR1) 
or a tagged transferrin receptor 1 (TrfR1) as a control, with or 
without Spred2, and subjected to analysis by immunoblotting. 
We did not stimulate cells with FGF, as overexpression of 
FGFR1 is autoactivating (Ong et al., 2000). A marked decrease 
in the level of ectopic FGFR1 was seen in the presence of 
Spred2, whereas levels of TrfR1 did not change significantly 
(Fig. 6 A), ruling out the possibility of a nonspecific effect on 
cotransfected protein levels by Spred2. No decrease in the lev-
els of downstream signaling components GRB2, C-RAF, or 
ERK was detectable either (Fig. 6 A), indicating that the effect 
of Spred2 is restricted to the receptor itself. A steady decrease 
in FGFR1 receptor levels was also seen in Spred2-expressing 
cells treated for various times with the translational inhibitor 
cycloheximide (Fig. S4 B). Moreover, Spred2-induced reduc-
tion in FGFR1 levels could be inhibited by treating cells with 
BafA, providing evidence for mediation of the decrease via the 
lysosomal degradation pathway (Fig. 6 B). Another lysosomal 
inhibitor, chloroquine, also gave similar results (Fig. S4 D). 
Next, we compared full-length Spred2 with the EVH1 Spred2 
mutant, which lacks the ability to interact with NBR1. Although 
full-length Spred2 decreased the level of ectopic FGFR1 as 
before, EVH1 Spred2 was incapable of inducing such reduc-
tion (Fig. 6 C). We also investigated the effect of Spred2 ex-
pression on endogenous FGFR levels and whether this was 
NBR1 dependent. We monitored endogenous FGFR2, as it was 
readily detectable in 293T cells. To make sure Spred2 was only 
expressed  after  NBR1  was  sufficiently  depleted,  we  used 
Tet-inducible Spred2 in the presence of control versus NBR1 
NBR1 knockdown efficiency by performing more rounds of 
siRNA transfection, we found that cell viability was severely 
compromised (Fig. S4 C). This was caused by induction of 
apoptosis and a specific NBR1 phenotype, as it was just seen 
with NBR1 oligonucleotides but not with nontargeting control 
siRNA oligonucleotides (Fig. S4 C) or oligonucleotides against 
P62 (not depicted). This suggests the existence of some vital 
functions for NBR1, which result in cell death when the protein 
is sufficiently depleted. Given that knockouts of both Spred1 
and -2 have been generated and are viable (Nobuhisa et al., 
2004; Bundschu et al., 2005; Inoue et al., 2005) and because ex-
pression  of  the  nonfunctional  EVH1-deleted  Spred2  mutant 
also does not affect cell viability, NBR1 knockdown lethality is 
very likely independent of Spred2. The nature of these vital 
functions remains to be determined.
We  next  set  out  to  investigate  whether  rescue  of  the 
Spred2–NBR1 interaction would also rescue the function of an 
EVH1-deleted  Spred2  mutant. While  investigating  the  inter-
action of NBR1 and Spred2, we made a surprising observation. 
Despite the fact that Spred2 interaction with endogenous NBR1 
in 293T cells required both the EVH1 and SPRY domains 
(Fig. 1 D), ectopic expression of NBR1 in 293T cells could res-
cue  the  interaction  with  an  EVH1-deleted  Spred2  mutant 
(Fig. 5 D). This was a cell type–specific phenomenon, as it 
could not be seen in other cell types investigated such as COS-7 
cells (Fig. 5 D). The ability to rescue the Spred2–NBR1 inter-
action in a cell type–specific manner for an otherwise noninter-
acting/nonfunctional EVH1 Spred2 mutant provided us with 
another way to test the functional significance of this interaction. 
We hypothesized that if the role of the EVH1 domain is to inter-
act with NBR1, ectopic expression of NBR1 in 293T cells 
should rescue the inability of the EVH1 Spred2 mutant to in-
hibit ERK1/2. This was in fact the case. Although expression of 
the EVH1 Spred2 mutant alone was not capable of inhibiting 
FGF2-mediated ERK1/2 activity, inhibition of ERK1/2 was re-
stored when NBR1 was coexpressed to rescue the interaction 
(Fig. 5 E). However, as before, NBR1 expression on its own did 
not affect ERK1/2 activity (Fig. 5 E). These data strongly sug-
gest that Spred2-mediated inhibition of ERK1/2 is dependent 
on the interaction with NBR1 and that the role of the EVH1 do-
main is to bind NBR1.
degradation. Fivefold more myc-Spred2 (or GFP for controls) was transfected to ensure that the majority of receptor-expressing cells also coexpressed myc-
Spred2. Cells were analyzed 12 h after transfection. (right) Densitometric analysis of FGFR1 degradation by myc-Spred2 in BafA-treated versus untreated 
cells. The p-value was calculated using a one-tailed paired t test (n = 3). (C) Spred2-induced decrease in FGFR1 levels is EVH1 dependent. (left) Contrary 
to WT myc-Spred2, EVH1 myc-Spred2 does not degrade FGFR1 in cotransfected 293T cells. Fivefold more myc-Spred2 or EVH1 myc-Spred2 (or GFP 
for controls) was transfected to ensure that the majority of receptor-expressing cells also coexpressed Spred2. (right) Densitometric analysis of the left. The   
p-value was calculated using a one-tailed paired t test (n = 3). (D) Depletion of NBR1 impairs Spred2-mediated degradation of endogenous FGFR2.   
(left) 293T cells were double transfected (with 100 pmol and then 50 pmol per 10-cm well) with either nonsilencing control (NSC) or NBR1-specific siRNA   
oligonucleotides. The Tet-inducible Spred2 construct was cotransfected with TR (1:6 ratio to ensure that every Spred-transfected cell also expressed TR) 
along with the oligonucleotides on the second transfection. Spred2 expression was induced 6 h before stimulation by 1 µg/ml Tet. The experiment was 
performed with two independent NBR1 siRNA oligonucleotides (Oligo1 and -2). Spred2-mediated FGFR2 degradation was significantly reduced with 
both NBR1 siRNA oligonucleotides. (right) Densitometric analysis of the left. The p-value was calculated using a one-tailed paired t test (n = 4). (E) Spred2 
alters receptor trafficking toward the lysosomal degradation pathway. In COS-7 cells transfected with FGFR2-GFP plus empty vector as control (negative 
control [NC]), the majority of endosomal receptors do not colocalize with LAMP2. In COS-7 cells transfected with FGFR2-GFP and WT myc-Spred2, most of 
the endosomal receptors colocalize with LAMP2 (+Spred2 FULL). However, deletion of the EVH1 domain results in the loss of this Spred2-induced LAMP2 
colocalization (+Spred2 EVH1). To identify Spred2-cotransfected cells, coverslips were also stained for Spred2 (blue) using an anti-Spred2 antibody (not 
depicted). Insets are higher magnification of their associated pictures. (F) The percentage of FGFR2-GFP colocalization with LAMP2 as in E was quantified 
and averaged. Measurements were from nine or more cells for each cotransfection from two separate experiments. The p-value was calculated using a 
one-tailed nonpaired t test (n = 9). (A–D and F) Error bars represent SEM. TUB, tubulin. Bars, 10 µm.
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pathways (for review see Miaczynska et al., 2004). For in-
stance, ERK1/2 activation downstream of the EGF receptor 
has been shown to be dependent on receptor endocytosis (Vieira 
et al., 1996; Kranenburg et al., 1999), whereas PLC- activa-
tion occurs on the membrane and does not require internaliza-
tion of the receptor (Vieira et al., 1996). ERK1/2 activation 
downstream of NGF in neurons has also been shown to require 
internalization of the receptor, whereas AKT activation does 
not (MacInnis and Campenot, 2002). Endosomal localization 
of certain signaling components and scaffolds is thought to be 
important for such selective propagation of downstream sig-
nals from specific endosomal compartments. For example, the 
GTP-bound active form of Rap1, a Ras-related small GTPase 
which can also activate ERK1/2, has been shown to be prefer-
entially enriched on endosomes (Ohba et al., 2003), and Spred2 
has also been shown to be capable of inhibiting Rap1 activa-
tion (King et al., 2005). Moreover, the scaffolding protein MP1, 
which acts to selectively activate ERK1 but not other MAPKs 
such as p38, has been shown to be enriched in late endosomes 
via the adapter protein p14 (Wunderlich et al., 2001; Teis et al., 
2002). Interestingly, in one of the aforementioned studies that 
came out while this manuscript was under revision, p14 was 
listed as a potential NBR1-interacting protein identified in a 
yeast two-hybrid screen (Waters et al., 2009). It remains to be 
determined whether this interaction occurs in vivo and plays a 
role in Spred2-mediated ERK1/2 inhibition via NBR1. Never-
theless, these considerations predict that in a short timescale, 
diversion of endosomal receptor trafficking by Spred2 could 
be preferentially affecting a subset of downstream signaling 
pathways  such  as  ERK1/2  that  require  specific  endosomal 
compartments as platforms for signal propagation.
Our findings implicate NBR1 as a novel regulator of re-
ceptor trafficking. The means by which NBR1 regulates recep-
tor  trafficking  are  currently  unknown,  but  several  lines  of 
evidence point toward an association with polyubiquitin as a 
siRNAs  as  before.  In  FGF2-stimulated  cells,  induction  of 
Spred2 expression resulted in a slight reduction of endogenous 
FGFR2, as expected (Fig. 6 D). However, knockdown of NBR1 
by specific siRNA oligonucleotides significantly reduced this 
effect (Fig. 6 D). As before, two independent siRNA oligo-
nucleotides were used, both of which gave similar results, ruling 
out the possibility of an off-target effect (Fig. 6 D). Therefore, 
we conclude that, as with inhibition of ERK1/2 activity, re-
duced levels of FGFRs by Spred2 appear to be, at least in part, 
NBR1 dependent.
Finally, we used a functional GFP-tagged FGFR2 (Ahmed 
et al., 2008) to elucidate the subcellular localization of active 
FGFR in Spred2- versus empty vector–transfected COS-7 cells. 
Like FGFR1, overexpression of FGFR2-GFP was autoactivat-
ing (unpublished data), so no additional FGF stimulation was 
necessary. In the absence of Spred2, only a fraction of endo-
somal  FGFR2-GFP  was  localized  to  LAMP2-positive  endo-
somes (Fig. 6, E and F). However, in the presence of Spred2, 
the majority of FGFR2-GFP endosomes were LAMP2 positive 
(Fig. 6, E and F). This increase in colocalization of the recep-
tor with LAMP2 could also be reversed by deletion of the 
Spred2 EVH1 domain (Fig. 6, E and F). Together, these results 
suggest that the EVH1/NBR1-dependent down-regulation of 
signaling by Spred2 is achieved via directed endosomal traf-
ficking of activated receptors into the late endosomal/lysosomal 
degradation pathway.
Discussion
Collectively, the evidence in this study reveals that the EVH1 
domain of Spred2 is required to engage with the late endosomal 
protein NBR1, and this is necessary for Spred2-mediated inhi-
bition of FGF signaling. Our results also suggest that Spred2 
functions by diverting receptors into the lysosomal degradation 
pathway via the interaction with NBR1 (Fig. 7). This adds to the 
accumulating body of evidence that implicates receptor traffick-
ing as a key hub for regulating signaling dynamics (Vieira et al., 
1996; Kranenburg et al., 1999; Sandilands et al., 2007; Sigismund 
et al., 2008; for review see Polo and Di Fiore, 2006). Several 
studies have also suggested a role for Sprouty in the regulation 
of downstream signaling by modulating the endocytic traffick-
ing of active receptors (Wong et al., 2002; Rubin et al., 2003; 
Kim et al., 2007). However, there seems to be a functional di-
vergence along with a structural divergence between Sprouty 
and Spred: Sprouty interferes with lysosomal degradation of the 
receptors by inhibiting Cbl-mediated receptor internalization 
(Wong et al., 2002; Rubin et al., 2003) and Hrs-dependent early 
to late endosomal transition (Kim et al., 2007), whereas Spred 
seems to promote lysosomal targeting of the receptors via en-
gaging with NBR1.
An intriguing issue is the fact that the inhibitory activity 
of Spred2 seems to be limited to the ERK1/2 pathway (Wakioka 
et al., 2001; Nonami et al., 2004; King et al., 2005). Several 
studies have highlighted the fact that endocytosis does not 
merely act as a means for receptor removal and degradation 
but that specific endosomal compartments themselves can   
act as selective platforms for certain downstream signaling 
Figure  7.  Schematic  representation  of  the  proposed  mechanism  for 
Spred. Via interacting with NBR1, Spred redirects activated receptors to 
the lysosomal degradation pathway. Down-regulation of downstream sig-
naling can be selective, as those pathways like ERK1/2 that need specific 
endosomal compartments for efficient activation are affected the most from 
a shift in the balance between different trafficking routes (e.g., sorting/ 
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and  -ERK1  and  mouse  monoclonal  anti–phospho-ERK1/2  (pERK1/2; 
clone E-4) antibodies were all purchased from Santa Cruz Biotechnology, 
Inc.  Mouse  monoclonal  antibodies  against  LAMP2  (clone  H4B4)  and 
MPR (clone 2G11) and rabbit polyclonal antibody against LAMP2 were 
purchased from Abcam. Anti-GRB2, –c-Raf, -Cav1, -EEA1, and -GM130 
rabbit polyclonal antibodies were purchased from Cell Signaling Technol-
ogy. Anti-Rab11 antibody was purchased from Invitrogen. LysoTracker 
red DND-99 and all fluorescently labeled (Cascade blue, Alexa Fluor 
488 [green], Alexa Fluor 594 [red], and Texas red) secondary antibodies 
were also purchased from Invitrogen. Nontargeting control siRNA and 
NBR1 siRNA oligonucleotides were purchased from Santa Cruz Biotech-
nology, Inc. and Thermo Fisher Scientific.
Cell culture, transfection, stimulation, and IP
Cell culture, transfections, and cell lysis were performed as in Sweet et al. 
(2008). siRNA transfections were performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. For multiple siRNA 
transfections, cells were seeded at 20%, and the first transfection was per-
formed immediately followed by second and third transfections at 24-h in-
tervals. For growth factor stimulation, cells were serum starved in serum-free 
DME for 6 h, and FGF2 to the final concentration of 20 ng/ml was added 
at various time points along with 10 µg/ml heparin (Sigma-Aldrich). IP was 
performed by the addition of antibody and Sepharose-G (Sigma-Aldrich) 
beads at the same time to the lysate followed by 1-h to overnight incuba-
tion at 4°C. Unless stated otherwise, 200–600 µg of whole cell lysate 
(WCL) was used. Beads were subsequently washed five times with 20× 
beads bed volume of lysis buffer and resuspended in 2× SDS-PAGE sample 
buffer before analysis by immunoblotting. Half of IP and 5–15 µg of WCL 
were usually loaded for immunoblots (IBs).
Immunofluorescence and confocal microscopy
For immunofluorescence, cells grown on coverslips were fixed with 4% 
paraformaldehyde-PBS, permeabilized with 0.2% Triton X-100–PBS before 
being blocked with 4% BSA-PBS, and subjected to primary and fluores-
cently labeled secondary antibodies in 4% BSA-PBS. For LysoTracker red 
staining, a 100-nM solution of the dye in culture medium was applied to 
the cells before fixation for 2 h. Coverslips were mounted on Mowiol solu-
tion and analyzed by laser-scanning confocal microscopy. Sequential sin-
gle section images were taken by a confocal microscope system (TCS SP2; 
Leica) using a 63× objective lens under low speed (200 Hz), minimum pin-
hole size (20 µm), and high EXPAND (6) settings to maximize image resolu-
tion. Final images were generated from averaging eight consecutive scans 
using the Leica confocal software. All further image processing (level ad-
justments, brightness and contrast settings, and overlaying) was performed 
by Photoshop 7.0 (Adobe) or ImageJ 1.37 software (National Institutes of 
Heath). For quantification of colocalizations, the ImageJ JACoP plug-in 
(Bolte and Cordelières, 2006) was used to calculate the percentage of co-
localization from Manders’ overlapping coefficients (fraction of green over-
lapping red).
Online supplemental material
Fig. S1 shows the interaction of Spred2 and NBR1 by directed yeast two-
hybrid, in vitro pull-down, and IP. Fig. S2 shows the colocalization of differ-
ent endocytic markers with NBR1. Fig. S3 shows the colocalization of NBR1, 
P62, and Spred2 and their co-migration in native gel as a single complex. 
Fig. S4 shows the regulation of ERK signaling, cell viability, and FGFR1 
degradation by Spred2 and NBR1. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200905118/DC1.
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potential mechanism. Ubiquitination plays a central role in the 
regulation of receptor trafficking, from target recognition and 
internalization to vesicle sorting and delivery. Key regulators 
of receptor trafficking such as epsins, Eps15, Hrs, and Tsg10 
all coordinate endocytic processes via ubiquitin-binding do-
mains that specifically recognize ubiquitinated targets (Kirkin 
and  Dikic,  2007).  NBR1  also  has  a  C-terminal  ubiquitin-
binding domain (the UBA domain), but the identity of ubiqui-
tinated cargoes that might interact with this domain is unknown 
at this moment. The two recent studies on NBR1 have sug-
gested that it might have a role in autophagy by targeting spe-
cific ubiquitinated cargoes to autophagosomes (Kirkin et al., 
2009; Waters et al., 2009). NBR1 was found to directly inter-
act with the autophagosomal protein LC3 and therefore act as 
an  adapter  for  specific  polyubiquitinated  cargoes  (Kirkin   
et al., 2009; Waters et al., 2009). Whether there are any links 
between the autophagic roles of NBR1 and its endocytic traf-
ficking roles uncovered in this study remains to be determined. 
Alternatively,  NBR1  might  have  a  similar  but  independent 
ubiquitinated cargo sorting role in the context of endocytic re-
ceptor trafficking. In this light, P62, which is similarly known 
to be involved in autophagy (Pankiv et al., 2007), has been 
also shown to regulate NGF receptor sorting via regulating 
TRAF6-dependent  K63  polyubiquitination  of  the  receptor 
(Geetha et al., 2005). Interestingly, in this study, we demon-
strated that NBR1, P62, and a fraction of Spred2 colocalize 
and form a protein complex in vivo (Fig. 1 B and Fig. S3,   
B and C). Finally, the endosomal adapter protein p14 has also 
been shown to regulate receptor trafficking (Teis et al., 2006). 
As mentioned earlier, whether p14 interacts with NBR1 in 
vivo, and, if it does so, whether regulation of receptor traffick-
ing and signaling by NBR1 depends on this interaction, awaits 
future investigations.
Materials and methods
Plasmid constructs
For yeast two-hybrid screen, the EVH1 domain of mSpred2 (amino acids 
1–125) was cloned into pYTH9 at SalI and BglII sites. N-terminal myc-
tagged full-length, EVH1, KBD, SPRY, and EVH1-ONLY mSpred2-pRK5 
and N-terminal 6× His–tagged EVH1-ONLY pDEST17 were made by Gate-
way  cloning  (Invitrogen)  according  to  manufacturer’s  instructions  as  in 
Sweet et al. (2008). N-terminal myc-tagged full-length mNbr1-PRK5,   
N-terminal GFP-tagged mNbr1-pcDNA DEST53, Tet-inducible mNbr1-pcDNA 
DEST31,  and  N-terminal  GST-tagged  C-terminal–ONLY(P856-Y988) 
mNbr1-pDEST15  vectors  were  also  made  by  Gateway  cloning.  The   
C-terminal GFP-tagged NBR1 construct was a gift from M. Gautel (King’s 
College London, London, England, UK). The N-terminally Flag-tagged P62 
construct was a gift from R. Layfield (University of Nottingham, Nottingham, 
England, UK). C-terminally GFP-tagged TrfR1 was a gift from J. Rappoport 
(University of Birmingham, Birmingham, England, UK), and C-terminally 
GFP-tagged FGFR2 was a gift from J. Ladbury (University College London, 
London,  England,  UK).  The  Tet-repressor  (TR)  expression  construct  (TR-
pcDNA6) was purchased from Invitrogen.
Reagents and antibodies
Rabbit polyclonal anti-Spred2 and mouse monoclonal anti-Flag (clone 
M2) and anti–-tubulin (clone DM 1A) as well as nonspecific rabbit IgG 
were all purchased from Sigma-Aldrich. P62 (clone 2C11) and NBR1 
(clone 6B11) mouse monoclonal antibodies were purchased from Ab-
nova. Mouse monoclonal anti-GFP (clone 3E1) and anti–c-myc (clone 
9E10) antibodies were obtained from Cancer Research UK monoclonal 
antibody services. Rabbit polyclonal anti-FGFR1, -FGFR2, -Rab5, -Rab7, JCB • VOLUME 187 • NUMBER 2 • 2009   276
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